7,546 press releases indexed under healthcare.
NEW YORK, Sept. 9, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Picard Medical Inc. (NYSE AMERICAN: PMI) breached their fiduciary duties to shareholders. According to a federal securities lawsuit,...
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / September 9, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. ("Fractyl" or the "Company") (NASDAQ:GUTS) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations ..
As interest in skin and hair wellness options grows in 2026, this NEOLISE Renewal review explores the brand-stated GHK-Cu, BPC-157, TB-500 and KPV formulation, how the prescription pathway is positioned for adults researching visible skin aging and hair thinning, what buyers receive with each plan, and the pricing, provider, pharmacy and FDA-compounding questions worth checking before enrolling.
WATERTOWN, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented positive initial results from the RESTORE-PV Phase 2 trial of DISC-3405 in patients with polycythemia vera (PV). The data, presented in a poster session at the 2026 Society of Hematologic Oncology (SOHO) annual meeting in Houston, TX, demonstrated that treatment with DISC-3405 increased hepcidin and lowered serum iron, translating to reduction in phlebotomy, controlled hematocrit, and improved symptom burden in patients with PV. These data will be featured in an oral presentation at the SOHO conference tomorr
This 2026 Direct Meds DirectMax update examines apomorphine's separate FDA approval history, how that differs from DirectMax's compounded prescription status, and what prospective patients should understand about the brand-stated sildenafil, tadalafil, and apomorphine combination before provider review.
(PR-inside.com) Hospital, Skilled Nursing Facility and Rural Health Clinics Remain Open and Continue Serving the Community MARSHALL, MO / ACCESS Newswire / September 9, 2026 / American Medical Administrators, Inc. ("AMA") today announced the completion of the transition of Fitzgibbon Hospital and related healthcare operations to new ownership and management following approval of the transaction by the U.S. Bankruptcy Court. Fitzgibbon Hospital, the Living Center Skilled Nursing Facility and the Fitzgibbon-operated Rural Health Clinics will remain open and continue serving patients and residents throughout the transition. Certain services and operations may be modified as AMA evaluates the needs of the facilities, patients and ..
Hospital, Skilled Nursing Facility and Rural Health Clinics Remain Open and Continue Serving the Community
Procedure reduces stomach size without surgery, giving patients another option for lasting weight loss. BALTIMORE, Sept. 9, 2026 /PRNewswire/ -- For the first time at MedStar Health, patients struggling with obesity who may not want, or may not qualify for traditional bariatric surgery,...
Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the "Company" or "Noveris") announces the results of its annual general and special meeting of shareholders held on September 4, 2026 (the "Meeting").A total of 21,697,593 common shares of the Company were represented at the Meeting, representing approximately 37.06% of the 58,548,051 common shares issued and outstanding and entitled to vote at the...
CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, today announced that it will present at the H.C. Wainwright 28 th Annual Global Investment Conference taking place September 14-16, 2026, in New York City. In addition, the management team will be available for one-on-one meetings during the conference.
SAN FRANCISCO, Sept. 9, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to...
HERZLIYA, Israel and CALGARY, Alberta, Sept. 9, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it intends to complete a private placement of up to 535,000 units of the Company (the "Units") at a...